Elicio Therapeutics, Inc.

NasdaqCM:ELTX Stock Report

Market Cap: US$210.5m

Elicio Therapeutics Management

Management criteria checks 4/4

Elicio Therapeutics' CEO is Bob Connelly, appointed in Oct 2018, has a tenure of 7.58 years. total yearly compensation is $1.89M, comprised of 33.5% salary and 66.5% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $537.34K. The average tenure of the management team and the board of directors is 4 years and 4.7 years respectively.

Key information

Bob Connelly

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage33.52%
CEO tenure7.6yrs
CEO ownership0.3%
Management average tenure4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Narrative Update • May 26

Aggressively accumulate equity shares and August 15 call options

Elicio Therapeutics (ELTX) presents a highly asymmetric, near-term clinical catalyst investment opportunity. Marketed at a current valuation of $189M—172x lower than its closest peer, Revolution Medicines (RVMD, $30B+ Cap)—ELTX is mispriced ahead of its mid-year Phase 2 data release for ELI-002 in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC).
Narrative Update • May 21

Favorable Auction Dynamics

While Merck and Amgen are the frontrunners for a KRAS-driven partnership, Elicio’s AMP platform is particularly attractive to a broader subset of "Big Pharma" companies that are currently facing a specific strategic gap: the inability of their existing portfolios to penetrate "cold" tumors like pancreatic (PDAC) and colorectal (CRC) cancers. It is most probable that big pharma is conducting due diligence into RVMD and ELTX in parallel and evaluating outcomes and potential synergies with their existing portfolios.
Narrative Update • May 05

Valuation: 15x upside potential

Determining the valuation for Elicio Therapeutics (ELTX) requires balancing the high-cost nature of specialized immunotherapy with the massive patient populations affected by KRAS mutations. Based on current oncology benchmarks and the clinical profile of the AMP-7P vaccine, here is the projected economic outlook.
Narrative Update • Apr 29

Study on track for success

As of April 28, 2026, based on the enrollment completion of the AMPLIFY-7P Phase 2 study in November 2024, approximately 40% to 45% of the MRD-negative cohort should have progressed by now if there were no treatment effect. This calculation is based on the clinical parameters and natural history data provided in the sources: 1.
Narrative Update • Feb 21

10 mg adjuvant = 100% mKRAS specific T-cell response rate

The 10 mg dose of Amph-CpG-7909 improves vaccine efficacy by providing an optimized level of Toll-like receptor 9 (TLR-9) stimulation that is precisely targeted to the lymph nodes, resulting in a 100% T cell response rate and significantly enhanced anti-tumor activity compared to lower doses. The specific mechanisms by which this dose and formulation improve efficacy include: 1.
Analysis Article • Feb 10

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Narrative Update • Jan 18

80-90% prob of success

Assuming a conservative 16-month median Disease-Free Survival (DFS) for the observation group—consistent with a nationwide, unselected (MRD-agnostic) surgical PDAC population—the probability that the AMPLIFY-7P Phase 2 study will show a statistically significant improvement in the treatment arm is estimated to be 80–90%. While the 16-month baseline represents a significantly more durable control group than the 5.0–6.4 month median seen in MRD-positive patients, the following factors derived from the sources support this high estimate: 1.
Seeking Alpha • Nov 07

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Summary ELTX is continuing its work on a KRAS vaccine in PDAC, with a phase 2 trial set to read out any day now. Earlier signals of efficacy of their phase 2 trial have shown biological correlation that suggests activity, but we still need to see outcomes of treatment. The company is heavily reliant on a positive read out in order to raise funds for further development. The potential upside here outweighs the admittedly huge downside risk, though. Read the full article on Seeking Alpha
Analysis Article • Aug 30

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO Compensation Analysis

How has Bob Connelly's remuneration changed compared to Elicio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$40m

Dec 31 2025US$2mUS$633k

-US$40m

Sep 30 2025n/an/a

-US$46m

Jun 30 2025n/an/a

-US$55m

Mar 31 2025n/an/a

-US$51m

Dec 31 2024US$2mUS$608k

-US$52m

Sep 30 2024n/an/a

-US$47m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$39m

Dec 31 2023US$678kUS$499k

-US$35m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$475k

-US$28m

Sep 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$872kUS$450k

-US$16m

Compensation vs Market: Bob's total compensation ($USD1.89M) is about average for companies of similar size in the US market ($USD1.59M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.

CEO

Bob Connelly (65 yo)

7.6yrs
Tenure
US$1,887,660
Compensation

Mr. Robert T. Connelly, also known as Bob, has been Chief Executive Officer and Director of Elicio Therapeutics Inc. since October 2018 and serves as its President. He served as a Director of Anchiano Ther...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Connelly
CEO, President & Director7.6yrsUS$1.89m0.26%
$ 537.3k
Allen Nissenson
Founder & Independent Directorno dataUS$90.26k0%
$ 0
Preetam Shah
Chief Strategy & Financial Officer and Treasurer1.2yrsUS$1.48mno data
Christopher Haqq
Executive VP6.6yrsUS$1.08m0.17%
$ 365.9k
Darrell Irvine
Co-Founderno datano datano data
Marc Wolfgang
Chief Technology Officerless than a yearno datano data
Peter DeMuth
Chief Scientific Officer4.3yrsUS$866.67k0.0040%
$ 8.5k
Megan Filoon
General Counsel3.3yrsno datano data
Esther Welkowsky
Senior Vice President of Clinical Development5.3yrsno datano data
Joy Seymour
VP & Head of Regulatory Affairs4yrsno datano data
Thian Kheoh
Senior Vice President of Biometrics3.3yrsno datano data
4.0yrs
Average Tenure
59yo
Average Age

Experienced Management: ELTX's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Connelly
CEO, President & Director7.6yrsUS$1.89m0.26%
$ 537.3k
Allen Nissenson
Founder & Independent Director2.9yrsUS$90.26k0%
$ 0
Darrell Irvine
Co-Founderno datano datano data
Julian Adams
Independent Chairman & Member of Scientific Advisory Board9.3yrsUS$120.76k0%
$ 0
Karen Wilson
Independent Director2.9yrsUS$97.76k0.010%
$ 21.4k
Robert Richard Ruffolo
Independent Director & Member of Scientific Advisory Board8.3yrsUS$82.76k0%
$ 0
Adrian Bot
Member of Scientific Advisory Boardno datano datano data
Jay Venkatesan
Director2.9yrsUS$77.76k0.93%
$ 1.9m
Carol Ashe
Independent Director5.8yrsUS$100.26k0%
$ 0
Emanuele Ostuni
Member of Scientific Advisory Boardno datano datano data
Yekaterina Chudnovsky
Director3.6yrsUS$77.76k29.51%
$ 62.1m
Pashtoon Kasi
Member of Scientific Advisory Boardno datano datano data
4.7yrs
Average Tenure
65yo
Average Age

Experienced Board: ELTX's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 17:37
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Elicio Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Soumit RoyJonesTrading Institutional Services, LLC
Boris PeakerJonesTrading Institutional Services, LLC